GC Biopharma, a top South Korean biopharmaceutical company, has entered into a Memorandum of Understanding (MOU) with the Thai Red Cross Society to strengthen their collaboration, especially in training for the production of plasma-derived medicines. This agreement marks the continuation of a partnership that started in 2015 when GC Biopharma helped TRCS set up a plasma fractionation facility in Thailand. The MOU shows a renewed dedication to growing their cooperation and building expertise in advanced plasma processing technologies within Thailand.
Health Technology Insights: Alpha Aesthetics Grows with New Clinic in Bonita Springs
Under the agreement, both organizations will work together to create and conduct training and exchange programs for local workers at the site. These programs are designed to share GC Biopharma’s advanced manufacturing knowledge and skills, helping to develop local production capabilities in Thailand. The partnership will also look into more joint efforts, like transferring technology related to plasma by-products and other strategic projects that match both organizations’ goals.
Hyoungjun Park, Vice President of GC Biopharma, said, “This MOU is a big step in spreading GC Biopharma’s advanced technology and production standards across Asia. By working with the TRCS, we want to achieve mutual growth while also helping the public.”
Health Technology Insights: Canary Speech Names Dr. Kang Hsu Jr. as Chief Medical Officer
Assoc. Prof. Dootchai Chaiwanichsiri, Director of the National Blood Centre at TRCS, added, “Improving our staff’s skills through focused training and direct knowledge transfer from GC Biopharma is crucial for keeping the quality, safety, and ongoing production of plasma-derived medicines in Thailand. This collaboration helps with human resource development and is an important move for technology transfer, supporting the country’s pharmaceutical and public health security.”
GC Biopharma is expanding its global business in plasma-derived therapies. In 2024, the company entered the U.S. immunoglobulin market and is working on partnerships across Southeast Asia, where local plasma fractionation is still limited.
This partnership with the Thai Red Cross Society shows GC Biopharma’s commitment to boosting regional production abilities and improving access to plasma therapy in Asia.
Health Technology Insights: FDA Approves BRINSUPRI for Non-Cystic Fibrosis Bronchiectasis Treatment
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
